Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Clinical trial NCT05154396 · UNKNOWN

Trial details

NCT number: NCT05154396
Sponsor: Chinese Academy of Medical Sciences
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-positive Breast Cancer

Start date: 2022-01-01
Primary completion: 2023-12-31
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.